Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 29, 2022 16:41 ET | Source: Biomerica, Inc.

Biomerica Reports Fiscal 2022 Year End Results

Revenues increase 162% for fiscal 2022 vs fiscal 2021 Revenues for fiscal Q4 2022 up 403% vs. fiscal Q4 2021 IRVINE, Calif., Aug. 29, 2022 (GLOBE NEWSWIRE) -- Biomerica, Inc. (Nasdaq: BMRA), (the...
July 14, 2022 08:19 ET | Source: Biomerica, Inc.

Walmart to Begin Selling Biomerica’s Aware® Breast Self Exam

Simple at-home device to increase sensitivity in breast self examsEarly detection of breast cancer saves livesBreast Cancer accounts for 1 in 3 new cases of cancer in women annually IRVINE,...
June 23, 2022 08:19 ET | Source: Biomerica, Inc.

Biomerica to Participate at BTIG Biotech Conference

IRVINE, Calif., June 23, 2022 (GLOBE NEWSWIRE) -- Biomerica Inc. (NASDAQ: BMRA) today announced that the Company’s CEO will participate at the 2022 BTIG Biotechnology Conference being held in person...
May 12, 2022 08:19 ET | Source: Biomerica, Inc.

Biomerica Announces CE Mark for Its H. pylori Diagnostic Test, hp+detect™

- Attaining CE Mark is a major step toward commercialization – - World Health Organization (WHO) lists H. pylori among the 16 antibiotic-resistant bacteria that pose the greatest threat to human...
April 26, 2022 08:19 ET | Source: Biomerica, Inc.

Biomerica Announces FDA Submission For a Test to Detect Helicobacter pylori (H. pylori), a Bacteria That Infects Approximately 35% of the US Population

Gastric cancer is the third most common cause of cancer related death in the world and over 80% of gastric cancers are attributed to H. pylori bacterial infection H. pylori infection is also a major...
April 14, 2022 08:37 ET | Source: Biomerica, Inc.

Biomerica Reports 111% Increase in Q3 Fiscal 2022 Revenues to $7.6 million vs. Q3 Fiscal 2021

Q3 Net loss per share of $0.01 vs. a net loss of $0.18 per share from same period last year InFoods® IBS diagnostic-guided therapy clinical trial results demonstrated statistically significant...
February 08, 2022 06:39 ET | Source: Biomerica, Inc.

Biomerica Announces Positive Topline Results from the Endpoint Clinical Trial of its InFoods® IBS Treatment for Patients with Irritable Bowel Syndrome

InFoods® IBS Diagnostic-Guided Therapy is the first therapy of its kind using science, diet and technology to identify patient specific foods, which when eliminated, help reduce the symptoms of IBS...
January 13, 2022 08:19 ET | Source: Biomerica, Inc.

Biomerica Reports Record Financial Results for Fiscal Second Quarter ended November 30, 2021

Revenues up 239% over prior year fiscal second quarter Customer orders backlog of over $4.0 million at November 30, 2021 Walmart began in-store and online sales of Biomerica’s EZ Detect™ Colon...
December 16, 2021 08:19 ET | Source: Biomerica, Inc.

Biomerica Announces Preliminary Second Quarter Revenue Increase of Approximately 238%, to Approximately $4.6 Million

InFoods® IBS Clinical Trial on Track for Completion in December with Topline Results Expected to be Announced in January, 2022. IRVINE, Calif., Dec. 16, 2021 (GLOBE NEWSWIRE) -- Biomerica, Inc....
November 19, 2021 08:19 ET | Source: Biomerica, Inc.

Biomerica Forms Scientific Advisory Board for Colorectal Cancer Screening

Chaired by Dr. Brooks Cash, Chief of Gastroenterology and Hepatology at the University of Texas Health Center at HoustonScientific Advisory Board to guide on programs to screen and test patients in US...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right